Pre-Market Most Active 28 Jan 2026: Allena Pharmaceuticals (ALNA) $0.08, catalyst
ALNA stock is among the most active pre-market names on NASDAQ as Allena Pharmaceuticals, Inc. trades at USD 0.075 after opening at USD 0.0641 on heavy volume. The equity shows a one-day change of +3.16% and reported 252,311,606 shares traded in the session snapshot. Investors are watching clinical and funding catalysts for the biotechnology company in the United States, while short-term volatility remains high for this microcap.
ALNA stock: pre-market trading and volume
Allena Pharmaceuticals (ALNA) is notable today for unusually high pre-market turnover with reported volume at 252,311,606 shares. The price range today has been between USD 0.06 and USD 0.1459, reflecting intraday swings that often appear in thinly traded healthcare microcaps.
ALNA stock: financials and key ratios
Latest company metrics show EPS -0.638 and a negative PE ratio of -0.12, underscoring that Allena is not profitable. Balance-sheet metrics include cash per share USD 0.92 and a current ratio of 2.11, which gives short-term liquidity cover for continuing clinical development.
ALNA stock: trading technicals and price action
ALNA stock opened at USD 0.0641 versus a previous close of USD 0.0727, with the current quote at USD 0.075. The wide intraday spread and the high volume point to significant volatility and low market depth, a typical pattern for NASDAQ-listed small biotech stocks.
ALNA stock: Meyka AI grade and analyst view
Meyka AI rates ALNA with a score out of 100: Score 58.66 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The C+ reflects reasonable liquidity and cash per share but persistent operating losses and limited commercialization progress.
ALNA stock: Meyka AI’s forecast and price target
Meyka AI’s forecast model projects a 12-month target of USD 0.15, comparing to the current price USD 0.075, an implied upside of 100.00%. Forecasts are model-based projections and not guarantees; outcomes depend on clinical readouts, regulatory updates, and financing events.
ALNA stock: risks, catalysts and sector context
Key catalysts for ALNA stock include clinical data updates for ALLN-346 and funding or partnership announcements. Major risks include trial setbacks, dilution from capital raises, and broader biotech sector weakness. The Biotechnology sector’s risk-on/risk-off swings will amplify ALNA’s moves on NASDAQ in the United States.
Final Thoughts
ALNA stock is trading as a highly volatile NASDAQ microcap with USD 0.075 quoted pre-market and heavy reported volume. Financially, Allena Pharmaceuticals shows negative EPS -0.638 and modest cash coverage USD 0.92 per share, supporting near-term operations but not commercialization. Meyka AI’s grade of C+ (58.66) — HOLD reflects this mix of liquidity and development risk. Our model projects a 12-month target of USD 0.15, implying 100.00% upside from the current quote USD 0.075, but investors should treat that as a model projection, not a guarantee. For traders, the combination of wide intraday ranges, thin depth, and event-driven catalysts suggests a strategy focused on position sizing, strict stops, and close monitoring of clinical or financing news. For longer-term investors, ALNA’s path depends on clinical progress for ALLN-346 and successful capital management in the competitive Biotechnology sector. Meyka AI provides this as AI-powered market analysis to help frame risks and opportunities, not investment advice.
FAQs
What is the current price and volume for ALNA stock?
ALNA stock is quoted at USD 0.075 pre-market with reported session volume of 252,311,606 shares. Intraday trading has ranged from USD 0.06 to USD 0.1459, indicating high volatility.
What does Meyka AI say about ALNA stock grade?
Meyka AI rates ALNA with a score out of 100: 58.66 which maps to C+ with a HOLD suggestion. The grade factors in benchmark, sector, financial growth, key metrics, and analyst data.
What is Meyka AI’s price forecast for ALNA stock?
Meyka AI’s forecast model projects a 12-month target of USD 0.15, versus the current USD 0.075, implying an upside of 100.00%. Forecasts are model-based projections and not guarantees.
What are the main risks for ALNA stock?
Primary risks for ALNA stock include negative operating results, trial or regulatory setbacks for ALLN-346, and dilution from capital raises. Sector-wide biotech swings also increase share volatility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
